Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis

Arthritis and Rheumatism

Volumn 64, Issue 2, 2012, Pages 542-548

  Walsh, Michael ^a   Flossmann, Oliver ^b   Berden, Annelies ^c   Westman, Kerstin ^d   Höglund, Peter ^d   Stegeman, Coen ^e   Jayne, David ^f  

^a ST JOSEPH S HOSPITAL   (Canada)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYELOBLASTIN;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CLINICAL TRIALS AS TOPIC; CREATININE; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS;

EID: 84856383829     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33361     Document Type: Article

References (30)

1. Jayne DR, Rasmussen N,. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 737-47. (Pubitemid 127758162)
2. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92. (Pubitemid 24065492)
3. Treatment of polyarteritis nodosa with cortisone: results after three years. Report to the Medical Research Council by the Collagen Diseases and Hypersensitivity Panel. Br Med J 1960; 1: 1399-400.
4. Frohnert PF, Sheps SG,. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43: 8-11.
5. Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T,. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009; 265: 496-506.
6. Slot MC, Tervaert JW, Franssen CF, Stegeman CA,. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 670-7. (Pubitemid 36126814)
7. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 621-31.
8. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44. (Pubitemid 36765101)
9. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al, for the European Vasculitis Study Group. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-9. (Pubitemid 41117433)
10. DeGroot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al, on behalf of the European Vasculitis Study Group. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-80.
11. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al, on behalf of the European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-8. (Pubitemid 47041083)
12. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-8. (Pubitemid 24334817)
13. Fine JP,. Regression modeling of competing crude failure probabilities. Biostatistics 2001; 2: 85-97.
14. Ambler G, Omar RZ, Royston P,. A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcome. Stat Methods Med Res 2007; 16: 277-98. (Pubitemid 47018663)
15. Royston P,. Multiple imputation of missing values: update. Stata J 2005; 5: 188-201. (Pubitemid 43708483)
16. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-84. (Pubitemid 36396745)
17. Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with a systemic vasculitis. Q J Med 1993; 86: 779-89. (Pubitemid 23352679)
18. Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Necrotizing vasculitis-relapse despite cytotoxic therapy. Adv Exp Med Biol 1993; 336: 477-81. (Pubitemid 24004973)
19. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008; 58: 2908-18.
20. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J,. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9: 842-52. (Pubitemid 28209094)
21. Kuross S, Davin T, Kjellstrand CM,. Wegener's granulomatosis with severe renal failure: clinical course and results of dialysis and transplantation. Clin Nephrol 1981; 16: 172-80. (Pubitemid 11018540)
22. Pedersen RS, Aunsholt NA,. Hemodialysis does not always protect against recurrence of Wegener's granulomatosis. Scand J Urol Nephrol 1990; 24: 223-5. (Pubitemid 20278556)
23. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG,. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-7. (Pubitemid 24011495)
24. Cohen G, Rudnicki M, Horl WH,. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. Kidney Int Suppl 2001; 78: S48-52. (Pubitemid 32144069)
25. Gibbons RA, Martinez OM, Garovoy MR,. Altered monocyte function in uremia. Clin Immunol Immunopathol 1990; 56: 66-80. (Pubitemid 20220886)
26. Girndt M,. Humoral immune responses in uremia and the role of IL-10. Blood Purif 2002; 20: 485-8. (Pubitemid 35007568)
27. Girndt M, Sester M, Sester U, Kaul H, Kohler H,. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001; 78: S206-11. (Pubitemid 32144099)
28. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al on behalf of the European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: 1036-43.
29. Touloumi G, Babiker AG, Kenward MG, Pocock SJ, Darbyshire JH,. A comparison of two methods for the estimation of precision with incomplete longitudinal data, jointly modelled with a time-to-event outcome. Stat Med 2003; 22: 3161-75. (Pubitemid 37220625)
30. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR,. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373-9. (Pubitemid 27028925)